Sign in
TerminatedPhase 2/3

Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

Key facts

Who runs it
Children's Hospital Medical Center, Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2/3
People taking part
6 people enrolled
Started
1 Oct 2021
Ended
1 Aug 2024
Type of study
Interventional
Treatments tested
  • RoadMAB precision dashboard
  • Infliximab precision dosing
Record updated
11 March 2026
Why it stopped
This was the Pilot study. The larger, confirmatory study has started

Who can take part

Age
6 years to 22 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Written informed consent form from the patient (≥18 years old) or from parent/legal guardian if patient is <18 years old
  • Written informed assent form from patient ≥11 years old
  • Age criteria: ≥6 years to ≤22 years of age
  • Diagnosis of Crohn's Disease
  • Starting infliximab (or biosimilar)
  • Anti-TNF naïve (never received infliximab, adalimumab, golimumab, certolizumab or anti-TNF biosimilar)
  • Fecal calprotectin >250 µg/g or fecal lactoferrin >10 µg/g (up to 6 weeks prior to starting infliximab) or endoscopic evidence of active Crohn's disease (up to 90 days prior to starting infliximab)
  • wPCDAI >12.5 (up to 6 weeks) prior to the first infliximab infusion
  • Negative urine pregnancy test for ALL female subjects
  • Negative TB (tuberculosis) blood test

Who cannot take part

  • Prior treatment with infliximab, adalimumab, certolizumab or golimumab (or anti-TNF biosimilar)
  • Active or prior evidence in past 12 months of internal (abdominal/pelvic) penetrating fistula(e)
  • Current ileostomy, colostomy, ileoanal pouch, and/or previous extensive small bowel resection leading to short bowel syndrome
  • Treatment with another investigational drug within four weeks
  • Treatment with intravenous antibiotics within four weeks
  • Treatment with intravenous corticosteroids within two weeks
  • Diagnosis of ulcerative colitis or inflammatory bowel disease-unspecified
  • Active Clostridium difficile infection or other known bacterial/viral gastroenteritis in last two weeks
  • History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
  • Inability or failure to provide informed assent/consent
  • Active intestinal stricture (luminal narrowing with pre-stenotic dilation >3mm), intra-abdominal abscess or perianal abscess
  • Planned continuation of 6-mercaptopurine or azathioprine (Imuran) during study
  • Planned continuation of methotrexate during study
  • Currently pregnant, breast feeding or plans in next 12 months to become pregnant

Where in United States

  • Cincinnati Children's HospitalCincinnati, United States

About the trial

What the trial wants to find out

Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents. Physicians need better ways to inform decisions on treatment.

Read full original descriptionShow less

The main reason for this research study is to determine if a computer program that formulates a dose based on a patient's blood testing results can better achieve the optimal drug level as compared to standard dosing.

The group in the trial

  • Interventional arm with precision dosingTreatment being tested

    The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.

    Treatment: RoadMAB precision dashboard and Infliximab precision dosing

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
11 March 2026